Immunomodulatory treatment of multiple sclerosis in Norway

Acta Neurologica Scandinavica

Volumn 115, Issue SUPPL.187, 2007, Pages 46-50

  Torkildsen, O ^a   Grytten, N ^a   Myhr, K M ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Evaluation; Guidelines; Immunomodulatory treatment; Multiple sclerosis; Prevalence

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; MITOXANTRONE; IMMUNOLOGIC FACTOR; PEPTIDE;

CLINICAL PRACTICE; COMPARATIVE STUDY; CONFERENCE PAPER; DATA BASE; EPIDEMIOLOGICAL DATA; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NORWAY; PATIENT INFORMATION; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; ARTICLE; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; IMMUNOLOGY; STATISTICS;

GUIDELINE ADHERENCE; HEALTH SERVICES ACCESSIBILITY; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MITOXANTRONE; MULTIPLE SCLEROSIS; NORWAY; PEPTIDES; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE; QUALITY OF HEALTH CARE;

EID: 34047229664     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2007.00846.x     Document Type: Conference Paper

References (21)

1. SWANK RL, LERSTAD O, STRøM A, BACKER J. Multiple sclerosis in rural Norway. Its geographical and occupational incidence in relation to nutrition. N Engl J Med 1952;246:721-8.
2. GRYTTEN N, GLAD SB, AARSETH JH, NYLAND H, MIDGARD R, MYHR KM. 50-year follow-up of the incidence of multiple sclerosis in Hordaland County, Norway. Neurology 2006;66:182-6.
3. SMESTAD C, SANDVIK L, HOLMøY T, HARBO HF, CELIUS EG. Differences in prevalence of multiple sclerosis between groups of non-western immigrants in Oslo, Norway. Poster European Committee on Treatment and Research in MS [ECTRIMS], 2006.
4. MILLER D, NOSEWORTHY J, COMPSTON A. Care of the person with multiple sclerosis. In: Compston A, et al. eds. McAlpine's multiple sclerosis. Philadelphia: Churchill Livingstone Elsevier, 2006.
5. THE IFNB MULTIPLE SCLEROSIS STUDY GROUP. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial.. Neurology 1993;43:655-61.
6. JACOBS LD, COOKFAIR DL, RUDICK RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94.
7. JOHNSON KP, BROOKS BR, COHEN JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995;45:1268-76.
8. PRISMS STUDY GROUP. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504.
9. JACOBS LD, BECK RW, SIMON JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000;343:898-904.
10. COMI G, FILIPPI M, BARKHOF F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-82.
11. http://www.legemiddelverket.no/upload/20022/publikasjon9-2000.pdf.
12. http://www.legemiddelverket.no/upload/20037/6.2001.pdf.
13. DAHL OP, AARSETH JH, MYHR K-M, NYLAND H, MIDGARD R. Multiple sclerosis in Nord-Trøndelag County, Norway: a prevalence and incidence study. Acta Neurol Scand 2004;109:378- 84.
14. GRøNNING M, MELLGREN SI. Multiple sclerosis in the two northernmost counties of Norway. Acta Neurol Scand 1985;72:321-7.
15. GRøNLIE SA, MYRVOLL E, HANSEN G, GRøNNING M, MELLGREN SI. Multiple sclerosis in north Norway and first appearance in an indigenous population. J Neurol 2000;47:129-33.
16. EDLAND A, NYLAND H, RIISE T, LARSEN JP. Epidemiology of multiple sclerosis in the county of Vestfold, eastern Norway: incidence and prevalence calculations. Acta Neurol Scand 1996;93:104-9.
17. MIDGARD R, RIISE T, NYLAND H. Epidemiologic trends in multiple sclerosis in Møre and Romsdal, Norway: a prevalence/incidence study in a stable population. Neurology 1991;41:887-92.
18. ALSTADHAUG KB, OLAVSEN J, SALVESEN R. Forekomst av multippel sklerose i Nordland 1970-99 [Incidence and prevalence of multiple sclerosis in Nordland County, Norway, 1970-1999]. Tidsskr Nor Laegeforen 2005;125:431-3.
19. PRESTHUS J. Report on the multiple sclerosis investigations in west Norway. Acta Neurol Scand 1960;35(suppl. 147):88-92.
20. LARSEN JP, AARLI JA, NYLAND H, RIISE T. Western Norway, a high-risk area for multiple sclerosis: a prevalence/incidence study in the county of Hordaland. Neurology 1984;34:1202-7.
21. CELIUS EG, VANDVIK B. Multiple sclerosis in Oslo, Norway: prevalence on 1 January 1995 and incidence over a 25-year period. Eur J Neurol 2001;8:463-9.